Eprubin 50 Injection contains Epirubicin 50 mg, an anthracycline anticancer medicine widely used in the treatment of various malignant conditions as part of established chemotherapy regimens. It helps inhibit the growth and multiplication of cancer cells by interfering with DNA replication and other critical cellular processes necessary for tumor development. The injection is administered under the supervision of oncology specialists and plays a vital role in comprehensive cancer treatment protocols.

Epirubicin works by binding to DNA and inhibiting the activity of enzymes required for cancer cell division and survival. This action disrupts the growth cycle of rapidly dividing malignant cells and promotes their destruction. Due to its proven effectiveness and broad antitumor activity, Epirubicin has become an important therapeutic option in modern oncology practice and is frequently incorporated into combination chemotherapy regimens.

The injection is commonly prescribed in the treatment of breast cancer, gastric cancer, ovarian cancer, soft tissue sarcoma, and various other malignancies as determined by an oncology specialist. It may be used alone or alongside other anticancer medicines depending on the patient's condition and treatment strategy. Careful monitoring during therapy helps optimize treatment outcomes while minimizing the risk of adverse effects associated with chemotherapy.

With the growing demand for advanced cancer therapies and specialized oncology care, Eprubin 50 Injection maintains strong relevance in the anticancer segment. Its established clinical efficacy, broad therapeutic applications, and inclusion in multiple chemotherapy protocols contribute to consistent market demand. The product offers excellent business potential and sustainable growth opportunities for retailers and distributors operating within the oncology pharmaceutical sector.

Eprubin 50 Injection may cause nausea, vomiting, hair loss, fatigue, weakness, mouth ulcers, loss of appetite, diarrhea, and injection site reactions. Bone marrow suppression, anemia, increased susceptibility to infections, cardiac toxicity, and liver function abnormalities may occur and require close medical supervision.

Eprubin 50 Injection is indicated for the treatment of breast cancer, gastric cancer, ovarian cancer, soft tissue sarcoma, bladder cancer, and other malignancies as determined by an oncology specialist. It helps control cancer cell growth and forms part of comprehensive chemotherapy treatment regimens.

This medication should be administered only by qualified healthcare professionals experienced in cancer chemotherapy. Regular monitoring of blood counts, cardiac function, liver function, kidney function, and overall patient condition is essential during treatment. Patients should immediately report symptoms such as fever, unusual bleeding, chest discomfort, severe fatigue, or signs of infection. Treatment should always be individualized according to the patient's condition and therapeutic response.

Store in a cool, dry place below 25°C, protected from direct sunlight and moisture. Keep the vial in its original packaging until use and out of reach of children. Do not use after the expiry date or if the packaging is damaged, opened, or shows signs of deterioration.